High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don't like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss.
The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
One of the largest global pharma companies would be created if a deal were to materialise.
BMY surged roughly 6% in premarket trading on the news before fading; the stock is now trading near flat. The asymmetric price reaction captures the market's immediate verdict: AZN shareholders see a value-destructive deal, while BMY holders see a potential premium exit.
European stock markets closed mostly higher in Monday trading as the Stoxx Europe gained 0.4%, Germa
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.
AstraZeneca stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb.
Medicus Pharma (NASDAQ:MDCX) announced it has put its chief medical officer in charge of UK subsidiary Antev Limited, consolidating leadership of the Teverelix clinical programme ahead of regulatory, late-stage development and partnering work. Dr Faisal Mehmud will become Antev’s chief...
A combination of the two pharmaceutical companies could create an entity valued at nearly $400 billion, according to the Financial Times
Combined group would rank fourth by market value
News of the day for Monday, August 3
Bristol Myers Squibb (BMY) just gave investors a strong quarter and a bigger outlook. Morgan Stanley read the same report and kept its rating exactly where it was. (The source of much of this article is a Morgan Stanley report shared with me.) Morgan Stanley sees the stock falling to $40, well ...
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, the steepest decline in the FTSE 100, as analysts struggled to explain why Britain's largest drugmaker would want to buy Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP). Jefferies described the reported talks...
Find insight on AstraZeneca , Bristol Myers Squibb, Hartalega and more in the latest Market Talks covering health care.
Aug 3 (Reuters) - U.S. stock index futures edged higher on Monday as signs of de-escalating tensions in the Middle East weighed on crude prices, while investors prepared for another week packed with
The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion.
The funding will advance its ATLAS trial, assessing lead candidate [Ac-225]RTX-2358, a FAP-targeted radiotherapeutic for advanced sarcomas.
↗️↘️AstraZeneca (AZN, UK:AZN), Bristol Myers Squibb (BMY): The drug companies are in talks to combine in a deal that would value the joint company at roughly $400 billion, the Financial Times reported.
U.S. stocks were on track to extend Friday’s rally as President Trump said he had canceled planned strikes on Iran, adding that peace talks would resume Monday afternoon.
Reports indicate AstraZeneca and Bristol-Myers Squibb are in early talks regarding a potential merger. If agreed, the combined group would rank among the largest pharmaceutical companies globally. The discussions are described as preliminary and no formal deal has been announced as at 31 July 2026. Bristol-Myers Squibb, traded as NYSE:BMY, is back in focus as investors consider what a tie up with AstraZeneca could mean for the $65.31 share price. The stock has logged returns of 5.2% over...
If maintained until close, the decline would be the stock’s biggest one-day percentage fall since the day of the 2024 U.S. presidential election.
Shares in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) fell 7% to 11,723p on Monday after news that Britain's biggest drugmaker is in talks to buy its US rival, Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP). A deal would create a pharmaceutical group worth close to $400 billion, ranking...
The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.
8.31am: AstraZeneca talks suggest 'reduced confidence' in outlook AstraZeneca's reported talks with Bristol Myers about creating a $400 billion company appear to make "limited strategic sense for Astra and would likely be subject to antitrust scrutiny, given the overlaps of their oncology...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
